These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22189977)

  • 1. The impact of human gene polymorphisms on HCV infection and disease outcome.
    Schaefer EA; Chung RT
    Semin Liver Dis; 2011 Nov; 31(4):375-86. PubMed ID: 22189977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
    J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
    J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.
    Rembeck K; Lagging M
    Pharmacogenomics; 2015; 16(10):1179-88. PubMed ID: 26250055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
    Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens.
    Tamaki N; Kurosaki M; Higuchi M; Takada H; Nakakuki N; Yasui Y; Suzuki S; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Ogawa S; Tanaka Y; Asahina Y; Izumi N
    PLoS One; 2015; 10(9):e0137351. PubMed ID: 26352693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.
    Sghaier I; Mouelhi L; Gazouani E; Morel V; Besma YL; Brochot E
    J Clin Virol; 2015 Aug; 69():184-9. PubMed ID: 26209404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
    Zampino R; Alessio L; Marrone A; Stanzione M; Boemio A; Grandone A; Minichini C; Pisaturo M; Starace M; Adinolfi LE; Sagnelli E; Coppola N
    Infez Med; 2015 Jun; 23(2):134-9. PubMed ID: 26110293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
    About F; Oudot-Mellakh T; Niay J; Rabiéga P; Pedergnana V; Duffy D; Sultanik P; Cagnot C; Carrat F; Marcellin P; Zoulim F; Larrey D; Hézode C; Fontaine H; Bronowicki JP; Pol S; Albert ML; Theodorou I; Cobat A; Abel L;
    PLoS One; 2015; 10(12):e0145105. PubMed ID: 26670100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.
    Tanaka Y
    Digestion; 2011; 84 Suppl 1():50-5. PubMed ID: 22156486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
    Takahashi H; Mizuta T; Oeda S; Isoda H; Nakashita S; Kawaguchi Y; Izumi N; Hirai M; Kurose K; Iwane S; Eguchi Y; Kimura S; Anzai K; Ozaki I
    J Viral Hepat; 2013 Apr; 20(4):e124-6. PubMed ID: 23490380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host genetics.
    Macías J; Vispo E; Pineda JA; Soriano V
    Curr Opin HIV AIDS; 2011 Nov; 6(6):491-500. PubMed ID: 21918436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
    Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
    Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
    J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.